Introduction
============

Blood viscosity is the internal dynamic resistance of blood to flow and determines the frictional force applied against the vessel walls. The determinants of blood viscosity are plasma viscosity, hematocrit (HcT), and aggregation and deformation abilities of erythrocytes, making blood a non-Newtonian fluid.^[@B1]^ Whole blood viscosity (WBV) may be predicted by previously validated formulas using HcT and plasma protein.^[@B2]^ Major risk factors for atherosclerosis such as high blood cholesterol, hypertension, aging, diabetes, metabolic syndrome, and obesity are also related with increased blood viscosity.^[@B3]^ Studies suggest that increased blood viscosity is at least as strong a predictor of cardiovascular events as diastolic blood pressure and low-density lipoprotein (LDL) cholesterol.^[@B4]^ Aortic valve sclerosis is the thickening of the aortic valve without a significant obstruction of the outflow, which may or may not accompany valvular calcification. It is not an infrequent finding with aging during cardiac imaging, and leaflet restriction is not hemodynamically significant,^[@B5]^ which is expressed by a maximal transvalvular velocity \< 2--2.5 m/s. Aortic valve stenosis is a precursor of aortic stenosis (AS) and an important predictor of coronary artery disease.^[@B6]^ Although coronary artery disease and AS share histopathological and etiological similarities, medical therapies such as statins have no effect on stopping or slowing AS,^[@B5]^ which necessitates the identification of other potential risk factors and, thus, new therapeutic options. On the other hand, the effects of blood viscosity on AS have not been studied adequately. In this context, we aimed to investigate the potential relationship between WBV and AS.

Methods
=======

We evaluated 94 patients with AS and 97 age- and gender-matched control subjects without AS selected from among individuals referred to the Echocardiography Laboratory of Ankara Numune Training and Research Hospital. Patients with AS, moderate-to-severe valvular disease, bicuspid aortic valve, history of rheumatic heart disease, left ventricular systolic dysfunction, symptomatic coronary artery disease, history of chronic kidney disease, paraproteinemia, acute blood loss or surgery, and history of hematological disease and anemia according to the patients' self-report and medical records were excluded from the study. Hypertension was defined as blood pressure \> 140/90 mmHg or use of antihypertensive drugs. Diabetes mellitus was defined as fasting blood glucose \> 125 mg/dL or use of antidiabetic treatment. Hypercholesterolemia was defined as total cholesterol \> 200 mg/dL or use of antilipidemic treatment. Laboratory tests for fasting blood glucose, lipid profile, creatinine levels, complete blood count, and total protein (TP) were performed with standard methods using commercially available laboratory kits.

AS was detected by using a commercially available echocardiography device (Vivid 7 pro, GE Vingmed, Horten, Norway) with a 2.5--3.5 MHz transducer. AS was defined as focal areas of increased echogenity and thickening of the aortic trileaflet valve without valve motion restriction and left ventricular outflow tract obstruction (aortic jet velocity \< 2.5 m/s with continuous wave Doppler ultrasound). The modified Simpson method was used to estimate the left ventricular ejection fraction. The diameter of the ascending aortic aorta and the presence of mitral annular calcification were also recorded. These measurements and evaluations were performed by 2 experienced cardiologists in accordance with the current recommendations of practice guidelines.^[@B7],[@B8]^

The estimation of WBV was carried out in both high shear rate (HSR = 208/s) and low shear rate (LSR = 0.5/s) via previously validated formulas,^[@B2],[@B9],[@B10]^ which utilize HcT and total plasma protein concentration. For HSR, the WBV (208/s) formula is as follows: (0.12 × HcT) + 0.17 (TP -- 2.07) and for LSR, WBV (0.5/ s) is: (1.89 × HcT) + 3.76 (TP -- 78.42), where HcT is hematocrit in %, TP is total protein concentration in g/L, and WBV is whole blood viscosity in centipoise (cP).

The statistical analyses were performed with IBM SPSS for Windows, version 22.0. The continuous variables are expressed as means ± SDs or medians (minimum -- maximum), where appropriate, and the categorical variables are expressed in percentages. The parametric test assumptions (normality and homogeneity of the variances) were tested before the groups were compared in terms of the continuous variables. The Shapiro--Wilk test was used when the continuous variables were not normally distributed. The homogeneity of the variances was tested using the Levine test. The continuous variables were tested with the *t*-test or the Mann-- Whitney *U*-test, where appropriate. The categorical variables were evaluated with the χ² test or the Fischer exact test. Factors affecting AS were determined with multiple stepwise logistic regression analysis. A p value \< 0.05 was considered statistically significant.

Results
=======

The baseline clinical, echocardiographic, and biochemical characteristics of the study groups are summarized in [Table 1](#T1){ref-type="table"}. Almost all the clinical, echocardiographic, and biochemical characteristics were similar in both groups. Aortic velocity was significantly higher in the patients with AS than in the control patients, as was expected (1.3 \[IQR: 1.1 -- 2\] m/s vs. 1.9 \[IQR: 1.8 -- 2.3\] m/s; p value \< 0.001). TP values were significantly higher in the AS group than in the control group (72.9 ± 5 g/L vs. 75.8 ± 6.1 g/L; p value \< 0.001). On the other hand, hemoglobin and HcT levels were similar in both groups (p value = 0.604 and p value = 0.431, respectively). High-density lipoprotein (HDL) cholesterol levels were significantly lower in the AS group than in the control group (45.9 ± 12.3 mg/dL vs. 49.8 ± 12.8 mg/dl; p value = 0.034), and LDL cholesterol levels tended to be higher in the AS group, but the difference was statistically insignificant (45.9 ± 12.3 mg/dL vs. 49.8±12.8 mg/dL; p value = 0.034). LDL cholesterol levels tended to be higher in the AS group, but the difference was statistically insignificant (147.2 ± 45.1 vs. 136.4 ± 38.8; p value = 0.079). WBV in LSR and HSR was higher in the AS group than in the control group (p value = 0.001 for both LSR and HSR) ([Table 2](#T2){ref-type="table"}).

In the multiple stepwise logistic regression analysis, AS was taken as a dependent variable. LDL, HDL, platelet count, ejection fraction, presence of mitral annular calcification, and WBV at LSR were included in Model 1 and LDL, HDL, platelet count, ejection fraction, presence of mitral annular calcification, and WBV at HSR were included in Model 2. In both models, WBV was an independent predictor of AS (p value \< 0.001) ([Table 3](#T3){ref-type="table"}).

###### 

Clinical, biochemical, and anthropometric characteristics of the 2 groups with and without aortic sclerosis[\*](#TFN1){ref-type="table-fn"}

                                      Aortic Sclerosis (-) (n=97)   Aortic Sclerosis (+) (n=94)   P value
  ----------------------------------- ----------------------------- ----------------------------- ----------
  Age (y)                             67.5±8.0                      67.1±9.2                      0.774
  Sex (male)                          30 (30.9)                     25 (26.6)                     0.509
  Body mass index (kg/m^2)^           25.20±1.4                     25.47±1.71                    0.168
  Smoking                             39 (40.2)                     35 (37.2)                     0.785
  Diabetes mellitus                   32 (33.0)                     23 (24.7)                     0.210
  Hyperlipidemia                      40 (41.2)                     35 (37.2)                     0.571
  Hypertension                        73 (75.3)                     75 (79.8)                     0.565
  Coronary artery disease             35 (36.5)                     35 (37.2)                     1.000
  LVEF (%)                            63 (50 -- 75)                 65 (50 -- 78)                 0.110
  Aortic jet velocity (m/s)           1.3 (1.1 -- 2)                1.9 (1.8 -- 2.3)              \< 0.001
  MAC                                 5 (5.2)                       21 (22.6)                     0.001
  Urea (mg/dL)                        33 (16 -- 69)                 36 (17 -- 90)                 0.309
  Serum creatinine (mg/dL)            0.83 (0.5 -- 1.6)             0.83 (0.5 -- 1.7)             0.406
  White blood cell count (10^3^/uL)   7.4±1.6                       7.5±1.9                       0.711
  Platelet (10^3^/uL)                 245.7±64.3                    261.9±74.5                    0.109
  Hemoglobin (g/dL)                   13.6±1.3                      13.7±1.3                      0.604
  Hematocrit (%)                      40.8±3.7                      41.2±3.8                      0.431
  Total protein (g/L)                 72.9±5.0                      75.8±6.1                      \< 0.001
  Fasting serum glucose (mg/dL)       102 (73 -- 348)               106.5 (75 -- 275)             0.570
  Total cholesterol (mg/dL)           216.7±44.5                    219.8±55.6                    0.665
  Triglycerides (mg/dL)               130 (32 -- 552)               139 (55 -- 397)               0.450
  LDL cholesterol (mg/dL)             136.4±38.8                    147.2±45.1                    0.079
  HDL cholesterol (mg/dL)             49.8±12.8                     45.9±12.3                     0.034
  Statins                             36 (37.1)                     34 (36.2)                     0.892
  Beta-blocker                        37 (38.1)                     36 (38.3)                     0.983
  ACE inhibitor /ARB                  69 (71.1)                     66 (70.2)                     0.889
  Acetyl salicylic acid               36 (37.1)                     39 (41.5)                     0.536

LVEF, Left ventricular ejection fraction; MAC, Mitral annular calcification; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; ARB, Angiotensin receptor blockers

Data are presented as mean±SD, median (interquartile range), or n (%).

###### 

Whole blood viscosity (WBV) of the patients at high shear rate (HSR) and low shear rate (LSR)[\*](#TFN2){ref-type="table-fn"}

                          Aortic Sclerosis (-) (n=97)   Aortic Sclerosis (+) (n=94)   P value
  ----------------------- ----------------------------- ----------------------------- ---------
  WBV at HSR, 208 s^-1^   56.4±20.9                     68.2±25.9                     0.001
  WBV at LSR, 0.5 s^-1^   16.9±1.0                      17.5±1.2                      0.001

Data are presented as mean±SD.

###### 

Stepwise logistic regression models of factors independently associated with aortic sclerosis

              OR      95% CI            P value
  ----------- ------- ----------------- ----------
  Model 1                               
       HDL    0.949   0.921 -- 0.978    0.001
       LDL    1.009   1.001 -- 1.018    0.028
       LSR    1.028   1.013 -- 1.043    \< 0.001
       LVEF   1.085   1.001 -- 1.177    0.048
       MAC    8.560   2.679 -- 27.351   \< 0.001
                                        
  Model 2                               
       HDL    0.950   0.922 -- 0.978    0.001
       LDL    1.009   1.001 -- 1.018    0.030
       HSR    1.732   1.279 -- 2.344    \< 0.001
       LVEF   1.084   1.000 -- 1.175    0.050
       MAC    8.623   2.697 -- 27.572   \< 0.001

HDL, High-density lipoprotein; LDL, Low-density lipoprotein; LSR, Low shear rate; LVEF, Left ventricular ejection fraction; MAC, Mitral annular calcification; HSR, High shear rate

Discussion
==========

In the present study, we found that, by comparison with patients without AS, patients with AS had high WBV at both LSR (0.5/s) and HSR (208/s). WBV at both LSR and HSR was an independent determinant of AS. This result suggests that WBV may have a potential role in the development of AS. AS shows a prevalence of about 10 % and an incidence of 1.7% to 8.8%. The progression of AS to clinical AS per year is \< 2%.^[@B5]^ Although the progression rate of AS is low, studies suggest that AS is closely associated with increased cardiovascular events and mortality.^[@B11],[@B12]^ Current medical treatments like statins do not slow or stop the progression of AS.^[@B13]^ In our study, we did not find a statistical difference between the AS and control groups apropos medical treatment. In this regard, the potential risk factors that may play a role in AS development and progression other than conventional ones should be determined with a view to improving therapeutic options. Dyslipidemia, hypertension, smoking, inheritance, obesity, diabetes, and metabolic syndrome are well-known risk factors for vascular sclerosis. However, a substantial portion of individuals with vascular sclerosis are free from classical risk factors. In this context, about 20% of myocardial infarctions are seen in the absence of these risk factors.^[@B14]^ Conventional risk factors fail to adequately depict the full picture. Elevated WBV is associated with an increased risk of acute myocardial infarction and cardiovascular death.^[@B15],[@B16]^ WBV may be the neglected part of this picture.

The significance of acute hyperviscosity syndromes like polycythemia vera and leukemia is well known, and immediate intervention is necessary. However, lesser elevation in viscosity in a chronic manner is not appreciated adequately. Acute hyperviscosity syndromes possess analogy with hypertensive crisis; and just like chronic hypertension, chronic hyperviscosity is associated with a shorter life expectancy. Both conditions may operate in synergy. Additionally, authors have suggested that chronic hyperviscosity be treated in the same manner as chronic hypertension.^[@B14]^ In our study, the prevalence of hypertension was not different between the groups with and without AS; nonetheless, WBV was elevated in the group with AS, which also shows the significance of hyperviscosity in the absence of hypertension.

One of the main mechanisms triggering valvular sclerosis is inflammation, which is also related with the activation of the leaflet endothelium with an increase in cell adhesion molecules and proinflammatory cytokines. Shear stress abnormalities may enhance the expression of proinflammatory genes and trigger tissue mineralization.^[@B17],[@B18]^ Increased viscosity is associated with increased shear stress for a given shear rate, and increased WBV may trigger valvular inflammation by increasing shear stress. In our study, the presence of mitral annular calcification in the patients was independently associated with AS. Both conditions are not simple degenerative processes and have similarities to atherosclerosis inasmuch as they share some risk factors. In a recent study, Çetin et al.^[@B19]^ demonstrated that WBV was an independent predictor of the presence of mitral annular calcification and limitation in annular motion. We also found that WBV was an independent predictor of AS apart from the presence of mitral annular calcification.

Our study has some limitations. In our study, we did not measure WBV directly by using a viscometer. Instead, we used previously validated equations for estimating WBV. Actual measurements may differ from the estimated viscosity calculated with regression-based equations. We employed single measurements of TP and HcT to calculate WBV. However, AS is a chronic process and multiple measurements at wider time intervals may be more appropriate to show the interaction.

Conclusion
==========

Higher whole blood viscosity levels were independently associated with aortic sclerosis at both high shear rate and low shear rate.
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